A virtualized infrastructure for molecular imaging research using a data grid model

2009 ◽  
Author(s):  
Jasper Lee ◽  
Grant Dagliyan ◽  
Brent Liu
Keyword(s):  
Molecular Imaging ◽  
Data Grid ◽  
Grid Model ◽  
Imaging Research

scholarly journals Clinical Molecular Imaging for Atherosclerotic Plaque

2021 ◽  
Vol 7 (10) ◽  
pp. 211
Author(s):  
Anton Kondakov ◽  
Vladimir Lelyuk
Keyword(s):  
Molecular Imaging ◽  
Cardiovascular Events ◽  
Vessel Wall ◽  
Somatostatin Receptor ◽  
Receptor Imaging ◽  
Somatostatin Receptor Imaging ◽  
Imaging Research ◽  
Patient Preparation ◽  
Atherosclerosis Imaging ◽  
Shed Light

Atherosclerosis is a well-known disease leading to cardiovascular events, including myocardial infarction and ischemic stroke. These conditions lead to a high mortality rate, which explains the interest in their prevention, early detection, and treatment. Molecular imaging is able to shed light on the basic pathophysiological processes, such as inflammation, that cause the progression and instability of plaque. The most common radiotracers used in clinical practice can detect increased energy metabolism (FDG), macrophage number (somatostatin receptor imaging), the intensity of cell proliferation in the area (labeled choline), and microcalcifications (fluoride imaging). These radiopharmaceuticals, especially FDG and labeled sodium fluoride, can predict cardiovascular events. The limitations of molecular imaging in atherosclerosis include low uptake of highly specific tracers, possible overlap with other diseases of the vessel wall, and specific features of certain tracers’ physiological distribution. A common protocol for patient preparation, data acquisition, and quantification is needed in the area of atherosclerosis imaging research.

scholarly journals Towards a scalable Scientific Data Grid model and services

2008 ◽  
Author(s):  
Azizol Abdullah ◽  
Mohamed Othman ◽  
Md Nasir Sulaiman ◽  
Hamidah Ibrahim ◽  
Abu Talib Othman
Keyword(s):  
Data Grid ◽  
Scientific Data ◽  
Grid Model

scholarly journals Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

Molecules ◽  
2021 ◽  
Vol 26 (9) ◽  
pp. 2451
Author(s):  
Paul Cumming ◽  
Milan Scheidegger ◽  
Dario Dornbierer ◽  
Mikael Palner ◽  
Boris B. Quednow ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Single Photon ◽  
Ex Vivo ◽  
Specific Binding ◽  
Photon Emission ◽  
Imaging Studies ◽  
Active Metabolites ◽  
Positron Emission ◽  
Imaging Research

Hallucinogens are a loosely defined group of compounds including LSD, N,N-dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and ex vivo, and the various molecular imaging studies with positron emission tomography (PET) or single photon emission computer tomography (SPECT). In general, molecular imaging can depict the uptake and binding distribution of labelled hallucinogenic compounds or their congeners in the brain, as was shown in an early PET study with N1-([11C]-methyl)-2-bromo-LSD ([11C]-MBL); displacement with the non-radioactive competitor ketanserin confirmed that the majority of [11C]-MBL specific binding was to serotonin 5-HT2A receptors. However, interactions at serotonin 5HT1A and other classes of receptors and pleotropic effects on second messenger pathways may contribute to the particular experiential phenomenologies of LSD and other hallucinogenic compounds. Other salient aspects of hallucinogen action include permeability to the blood–brain barrier, the rates of metabolism and elimination, and the formation of active metabolites. Despite the maturation of radiochemistry and molecular imaging in recent years, there has been only a handful of PET or SPECT studies of radiolabeled hallucinogens, most recently using the 5-HT2A/2C agonist N-(2[11CH3O]-methoxybenzyl)-2,5-dimethoxy- 4-bromophenethylamine ([11C]Cimbi-36). In addition to PET studies of target engagement at neuroreceptors and transporters, there is a small number of studies on the effects of hallucinogenic compounds on cerebral perfusion ([15O]-water) or metabolism ([18F]-fluorodeoxyglucose/FDG). There remains considerable scope for basic imaging research on the sites of interaction of hallucinogens and their cerebrometabolic effects; we expect that hybrid imaging with PET in conjunction with functional magnetic resonance imaging (fMRI) should provide especially useful for the next phase of this research.

Sign in / Sign up

Export Citation Format

Share Document